In agreement with data reported on the overall population—i.e., stage-agnostic prevalence of EGFR mutations in NSCLC—we found that the lepidic (37.3%) and acinar (21.7%) subtypes were those most enriched for EGFR mutations also in early-stage NSCLC, whereas the solid and mucinous subtypes harbored EGFR mutations in only 2.5% and 3.8% of cases (Figure 5A). This evidence concerns the gene EGFR and non-small cell lung carcinoma.